Navigation Links
Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
Date:3/13/2008

SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that it has initiated a Phase 2 study of RAV12, its lead clinical product, in combination with gemcitabine in the treatment of patients with metastatic pancreatic cancer.

The Phase 2 Pancreatic Cancer Study will be conducted at approximately 20 institutions in the US. The first institution to open the trial is the Fox Chase Cancer Center in Philadelphia, PA. Eight sites will participate through the clinical trials consortium, the Pancreatic Cancer Research Team. More information regarding the study can be found at http://www.clinicaltrials.gov.

After an initial dose-escalation run-in segment of approximately 18 patients, the Phase 2 trial will enroll 63 patients in an efficacy segment. The target dose and schedule of RAV12, 0.75 mg/kg twice weekly, was chosen in a recently completed Phase 1/2a trial that involved 53 patients. Final analysis of the Phase 1/2a study will be available the third quarter of 2008.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, and colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly cytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibody alters cellular signaling required for cell survival. RAV12 is highly efficacious in human colon, gastric, and pancreatic tumor xenograft models in vivo and has been found to be well tolerated in repeat dose primate toxicology studies.

About Pancreatic Cancer

Adenocarcinoma of the pancreas is a major unmet medical need and represents the fourth leading cause of cancer death in the US. Approximately 34,000 new cases of pancreatic cancer are reported in the US each year. Five-year survival rates are approximately 1% to 2%. Gemcitabine was approved for use in pancreatic cancer a decade ago, but little advance in treatment outcomes has occurred since.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast and ovarian cancer.

On November 12, 2007, Raven and VaxGen Inc. (OTC: VXGN.PK), a biopharmaceutical company, announced that their respective boards of directors unanimously approved a definitive merger agreement. The merger is expected to create a drug development company with a robust pipeline of monoclonal antibody candidates in oncology, proprietary antibody discovery platforms, biopharmaceutical manufacturing capabilities and sufficient cash to fund operations at least through the end of 2009. The merger is expected to close in the first half of 2008.


'/>"/>
SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
2. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
4. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
7. Inclinix Announces New Patent for Expert System Platform
8. Genzyme Announces Presentation of New Positive Data on Carticel(R)
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... CALABASAS, Calif. , June 14, 2017 ... with the City of Fremont ... chain of the bio-pharma industry in California ... sharing technology, enabling executive networking, and fostering workforce development. ... the development and growth of start-ups, as well as ...
(Date:6/11/2017)... -- Eli Lilly and Company (NYSE: LLY ) announced ... galcanezumab, an investigational treatment for the prevention of episodic ... secondary endpoints for galcanezumab compared to placebo at both ... and REGAIN) will be presented today at the American ... Boston . "The detailed Phase ...
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Dr. Richard Amato, a ... of his practice, Advanced Periodontics and Dental Implant Center of Connecticut. As part of ... and waiting areas. The renovations are intended to improve patient comfort while making it ...
(Date:6/27/2017)... ... , ... Today, June 27th is PTSD Awareness Day. Over half a million ... adequate care due to lack of effective treatments, fear of stigma or insufficient government ... untreated, veterans are at an increased risk for self-destructive behavior, including alcohol/drug abuse, depression, ...
(Date:6/27/2017)... CA (PRWEB) , ... June 27, 2017 , ... East ... crooked bites can indicate about early life experiences. What happens to a woman during ... that stresses after birth can also take a toll on a baby’s long-term health. ...
(Date:6/26/2017)... ... June 26, 2017 , ... Torrance dentist, Dr. Robert ... one of the most noticeable aspects of a person’s appearance. A healthy, radiant smile ... born with beautiful, balanced teeth, everyone can have the smile of their dreams with ...
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. ... Medicine Specialists, in collaboration with the Fertility Center of California, is pleased to ... (percutaneous epidydimal sperm aspiration) and TESA (percutaneous testicular sperm extraction). These minimally invasive ...
Breaking Medicine News(10 mins):